# Revelation Biosciences (REVB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/REVB
## Company Profile
- Ticker: REVB
- Exchange: NASDAQ
- Sector: MedTech
- Location: United States
- Tags: MedTech
## Stock Data
- Close: 0.7522 USD
- Market cap: 4142925.2 USD
- Last updated: 2026-10-06
## Business Overview
### Innate Immune Modulation Company
Revelation Biosciences develops therapies intended to rebalance inflammation in acute and chronic disease. Its lead formulation activates Toll-like receptor 4 to produce a controlled innate immune response.
### Gemini Lead Candidate
Gemini is a proprietary formulation of phosphorylated hexaacyl disaccharide. Rather than broadly suppressing immunity, the candidate is designed to precondition and recalibrate the inflammatory response.
### Acute Kidney Injury Program
The primary development program targets acute kidney injury associated with cardiac surgery. Revelation is preparing an adaptive pivotal study intended to evaluate prevention or reduction of clinically significant kidney injury.
### Clinical and Preclinical Evidence
Gemini has been evaluated in Phase 1 studies and in preclinical models of acute kidney injury, chronic kidney disease, and infection. These data support selection of dose, timing, and endpoints for later-stage development.
### Manufacturing Readiness
The company has initiated GMP manufacturing of Gemini and placebo for its planned clinical program. External manufacturers, a renal-focused contract research organization, and scientific advisers support execution.
## Why The Stock Is Moving

As of Oct 6, 2026, REVB closed down 3.20% at $0.7522. No new same-company headline was identified in the current news window.

## Future Catalysts

- Initiation of the adaptive pivotal Phase 2/3 study of Gemini in acute kidney injury in the fourth quarter of 2026.

## Recent News
- 2022-08-15 21:30 EST — [Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress](https://biopharmsignal.com/news/REVB/revelation-biosciences-inc-announces-financial-results-for-the-three-and-six-mon-fbbc81f2) — Source: Revelation Biosciences
- 2022-07-29 15:45 EST — [Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering](https://biopharmsignal.com/news/REVB/revelation-biosciences-inc-announces-closing-of-5-million-public-offering-95bbd4cb) — Source: Revelation Biosciences
- 2022-07-26 12:15 EST — [Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering](https://biopharmsignal.com/news/REVB/revelation-biosciences-inc-announces-pricing-of-5-million-public-offering-ccbe0adb) — Source: Revelation Biosciences
- 2022-07-22 22:30 EST — [Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis](https://biopharmsignal.com/news/REVB/revelation-biosciences-inc-announces-topline-data-for-phase-1b-clear-clinical-st-8cabb9a7) — Source: Revelation Biosciences
- 2022-07-14 13:00 EST — [Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis](https://biopharmsignal.com/news/REVB/revelation-biosciences-inc-completes-database-lock-for-its-phase-1b-clear-clinic-11887762) — Source: Revelation Biosciences